Page 9 - Developing Drugs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SILVER SPRING, Md., Feb. 22, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued guidances for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes COVID-19. "The FDA is committed to identifying efficient ways to modify medical products that either are in the pipeline or have been authorized for emergency use to address emerging variants," said Acting FDA Commissioner Janet Woodcock, ...

Press release content from Accesswire. The AP news staff was not involved in its creation. Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study January 20, 2021 GMT TORONTO, ON / ACCESSWIRE / January 20, 2021 / Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses a...

Theralase Technologies Inc.: Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (" UA") has received site Institutional Review Board (" IRB") approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (" NMIBC") Clini...

Theralase Technologies Inc.: Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Virginia Urology (" VU") has received site Institutional Review Board (" IRB") approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (" NMIBC") Clinical Stud...